The aim of this study was therefore to analyse tumour-specific expression of HMGCR by immunohistochemistry in tissue microarrays (TMAs) with primary tumour specimens from incident CRC cases diagnosed within a large, prospective cohort study, and to explore its relationship with established clinicopathological and tumor biological parameters, and survival. This evidence concerns the gene HMGCR and colorectal carcinoma.